FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4309884908> ?p ?o ?g. }

• W4309884908 endingPage "207" @default.
• W4309884908 startingPage "193" @default.
• W4309884908 abstract "Recently, complicated intra-abdominal infections (cIAI) have been caused not only by Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, and Pseudomonas aeruginosa, but also by extended-spectrum β-lactamase-producing Enterobacterales members. Ceftolozane–tazobactam (CTLZ–TAZ) is considered to exhibit therapeutic effects against cIAI. Studies on the concentrations of antibiotics in abdominal tissues directly affected by cIAI are limited. Therefore, in this study, we investigated the pharmacokinetics of CTLZ–TAZ in abdominal tissue and simulated the administration regimen required to achieve the pharmacodynamic target for cIAI-causing bacteria. Patients scheduled for elective lower gastrointestinal surgery were intravenously administered preoperative CTLZ–TAZ (1 g CTLZ and 0.5 g TAZ). Plasma, peritoneal fluid, peritoneum, and subcutaneous adipose tissue samples were collected during the surgery, and CTLZ as well as TAZ concentrations were measured. The noncompartmental and compartmental pharmacokinetic parameters were then estimated. Site-specific pharmacodynamic target attainment analysis using 1.5 g of CTLZ–TAZ was performed. CTLZ–TAZ was administered to nine patients (once to five patients and twice to four patients). The mean peritoneal fluid-to-plasma ratio (one dose/two doses) for CTLZ was 0.74/1.15, which was slightly higher than the mean peritoneal fluid-to-plasma ratio for TAZ (0.95/1.13). The ratio for subcutaneous adipose was lower than those for peritoneal fluid and peritoneum tissues. We also discovered that the average ratio of CTLZ and TAZ concentrations in all tissues was maintained at or above 2:1. In our investigation of pharmacodynamic target attainment in each tissue, the desired bactericidal effect was attained with all CTLZ–TAZ (1.5 g) administration regimens [q12h (3 g/day), q8h (4.5 g/day), and q6h (6 g/day)]. To the best of our knowledge, this is the first study investigating the optimal pharmacodynamic level of CTLZ–TAZ in the abdominal tissue against cIAI-causing bacteria. This study also serves as a guideline for designing an optimal administration regimen based on pharmacodynamic target attainment for cIAI-causing bacteria. The institutional review board of Hiroshima University Hospital, CRB6180006. The Japan Registry of Clinical Trials, jRCTs061190025." @default.
• W4309884908 created "2022-11-29" @default.
• W4309884908 creator A5003535230 @default.
• W4309884908 creator A5023163961 @default.
• W4309884908 creator A5041730098 @default.
• W4309884908 creator A5047110554 @default.
• W4309884908 creator A5053985948 @default.
• W4309884908 creator A5059571413 @default.
• W4309884908 creator A5062066289 @default.
• W4309884908 creator A5074511391 @default.
• W4309884908 creator A5085091036 @default.
• W4309884908 creator A5085289852 @default.
• W4309884908 creator A5089533787 @default.
• W4309884908 date "2022-11-24" @default.
• W4309884908 modified "2023-09-26" @default.
• W4309884908 title "Ceftolozane–Tazobactam Pharmacokinetics in the Abdominal Tissue of Patients Undergoing Lower Gastrointestinal Surgery: Dosing Considerations Based on Site-Specific Pharmacodynamic Target Attainment" @default.
• W4309884908 cites W1944076487 @default.
• W4309884908 cites W1969500929 @default.
• W4309884908 cites W1976078168 @default.
• W4309884908 cites W1996296627 @default.
• W4309884908 cites W2036799160 @default.
• W4309884908 cites W2053494180 @default.
• W4309884908 cites W2065177826 @default.
• W4309884908 cites W2069662153 @default.
• W4309884908 cites W2077365277 @default.
• W4309884908 cites W2087526401 @default.
• W4309884908 cites W2129772896 @default.
• W4309884908 cites W2137889019 @default.
• W4309884908 cites W2146291304 @default.
• W4309884908 cites W2149186506 @default.
• W4309884908 cites W2152944495 @default.
• W4309884908 cites W2159554754 @default.
• W4309884908 cites W2312666860 @default.
• W4309884908 cites W2586169463 @default.
• W4309884908 cites W2612400206 @default.
• W4309884908 cites W2619325951 @default.
• W4309884908 cites W2726090857 @default.
• W4309884908 cites W2770189627 @default.
• W4309884908 cites W2781179959 @default.
• W4309884908 cites W2797086108 @default.
• W4309884908 cites W2936169514 @default.
• W4309884908 cites W3013841357 @default.
• W4309884908 cites W3031310847 @default.
• W4309884908 cites W3087056791 @default.
• W4309884908 cites W3144495188 @default.
• W4309884908 cites W4226358716 @default.
• W4309884908 cites W4292528167 @default.
• W4309884908 doi "https://doi.org/10.1007/s40121-022-00720-x" @default.
• W4309884908 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36418742" @default.
• W4309884908 hasPublicationYear "2022" @default.
• W4309884908 type Work @default.
• W4309884908 citedByCount "0" @default.
• W4309884908 crossrefType "journal-article" @default.
• W4309884908 hasAuthorship W4309884908A5003535230 @default.
• W4309884908 hasAuthorship W4309884908A5023163961 @default.
• W4309884908 hasAuthorship W4309884908A5041730098 @default.
• W4309884908 hasAuthorship W4309884908A5047110554 @default.
• W4309884908 hasAuthorship W4309884908A5053985948 @default.
• W4309884908 hasAuthorship W4309884908A5059571413 @default.
• W4309884908 hasAuthorship W4309884908A5062066289 @default.
• W4309884908 hasAuthorship W4309884908A5074511391 @default.
• W4309884908 hasAuthorship W4309884908A5085091036 @default.
• W4309884908 hasAuthorship W4309884908A5085289852 @default.
• W4309884908 hasAuthorship W4309884908A5089533787 @default.
• W4309884908 hasBestOaLocation W43098849081 @default.
• W4309884908 hasConcept C104317684 @default.
• W4309884908 hasConcept C111113717 @default.
• W4309884908 hasConcept C112705442 @default.
• W4309884908 hasConcept C126322002 @default.
• W4309884908 hasConcept C126894567 @default.
• W4309884908 hasConcept C141071460 @default.
• W4309884908 hasConcept C171089720 @default.
• W4309884908 hasConcept C2777058267 @default.
• W4309884908 hasConcept C2777288759 @default.
• W4309884908 hasConcept C2777402170 @default.
• W4309884908 hasConcept C501593827 @default.
• W4309884908 hasConcept C547475151 @default.
• W4309884908 hasConcept C55493867 @default.
• W4309884908 hasConcept C71924100 @default.
• W4309884908 hasConcept C86803240 @default.
• W4309884908 hasConcept C89423630 @default.
• W4309884908 hasConcept C90924648 @default.
• W4309884908 hasConcept C98055416 @default.
• W4309884908 hasConcept C98274493 @default.
• W4309884908 hasConceptScore W4309884908C104317684 @default.
• W4309884908 hasConceptScore W4309884908C111113717 @default.
• W4309884908 hasConceptScore W4309884908C112705442 @default.
• W4309884908 hasConceptScore W4309884908C126322002 @default.
• W4309884908 hasConceptScore W4309884908C126894567 @default.
• W4309884908 hasConceptScore W4309884908C141071460 @default.
• W4309884908 hasConceptScore W4309884908C171089720 @default.
• W4309884908 hasConceptScore W4309884908C2777058267 @default.
• W4309884908 hasConceptScore W4309884908C2777288759 @default.
• W4309884908 hasConceptScore W4309884908C2777402170 @default.
• W4309884908 hasConceptScore W4309884908C501593827 @default.
• W4309884908 hasConceptScore W4309884908C547475151 @default.
• W4309884908 hasConceptScore W4309884908C55493867 @default.
• W4309884908 hasConceptScore W4309884908C71924100 @default.

• next